Screener
Revolution Medicines, Inc. RVMD Impairment Charges
Impairment Charges at other companies
Other financials
Where this comes from
Reported directly by Revolution Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.
The source filing: Revolution Medicines, Inc.’s 10-Q, filed November 5, 2025.
- Filed
- Nov 5, 2025
- Fiscal quarter
- Q3 FY2025
- Calendar quarter
- Q3 2025
- Accession
- 0001193125-25-266923
| Line item | Nine Months Ended September 30, 2025 | Nine Months Ended September 30, 2024 |
|---|---|---|
| Non-cash interest expense on liability related to sale of future royalties | 12,294 | — |
| Net amortization of premium or discount on marketable securities | (23,277) | (35,739) |
| Amortization of operating lease right-of-use asset | 5,542 | 2,811 |
| Impairment of assets | — | 2,761 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | — | 1,254 |
| Prepaid expenses and other current assets | (6,290) | (4,586) |
| Accounts payable | 20,036 | (35,828) |
Item 1. Financial Statements.
FAQ
- What is Revolution Medicines, Inc.'s impairment charges?
- Revolution Medicines, Inc. (RVMD) reported impairment charges of $0 in Q3 2025.
- What does impairment charges mean?
- Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.
Ask your AI about Revolution Medicines, Inc.'s impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude